1-ethyl-2-methyl-1H-naphth<2,3-d>imidazole | 80079-34-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-ethyl-2-methyl-1H-naphth<2,3-d>imidazole
• 英文别名: 1-Ethyl-2-methyl-1H-naphtho[2,3-D]imidazole；3-ethyl-2-methylbenzo[f]benzimidazole
• CAS: 80079-34-1
• 化学式: C₁₄H₁₄N₂
• 分子量: 210.279
• InChiKey: NEJBVLKPEBCKII-UHFFFAOYSA-N

物化性质

• 熔点：
  52 °C(Solv: ethanol (64-17-5); water (7732-18-5))
• 沸点：
  405.7±14.0 °C(Predicted)
• 密度：
  1.12±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-ethyl-2-methyl-1H-naphth<2,3-d>imidazole 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 乙腈 为溶剂， 反应 4.5h， 生成 1H-萘并[2,3-d]咪唑正离子,1,3-二乙基-2-[3-(3-乙基-2(3H)-苯并噻唑亚基)-1-丙烯基]-,碘化
  参考文献：
  名称：

  Synthesis and substance P antagonist activity of naphthimidazolium derivatives

  摘要：

  The synthesis of unsymmetrical naphth[2,3-d]imidazolium and bridged naphth[2,3-d]imidazolium derivatives and their substance P (SP) antagonist activity are described. All compounds were evaluated for their ability to displace SP from neurokinin-1 (NK-1) receptor sites using standard receptor binding methodology (rat forebrain membrane). 1,3-Diethyl-2-[3-(1,3-dihydro-1,3,3-trimethyl-2H-indol-2-ylidene)-1-propenyl]-1H-naphth[2,3-d]imidazolium chloride (7a), a representative compound in this series, was further evaluated for SP antagonist activity in a guinea pig ileum contractility assay. In vivo SP antagonist activity of 7a was demonstrated using SP-induced salivation and paw edema models performed in rats.

  DOI：

  10.1021/jm00085a015
• 作为产物：
  描述：

  2,3-二氨基萘 、 alkaline earth salt of/the/ methylsulfuric acid 在 氢氧化钾 、 硫酸 作用下， 以 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 7.0h， 生成 1-ethyl-2-methyl-1H-naphth<2,3-d>imidazole
  参考文献：
  名称：

  Synthesis and substance P antagonist activity of naphthimidazolium derivatives

  摘要：

  The synthesis of unsymmetrical naphth[2,3-d]imidazolium and bridged naphth[2,3-d]imidazolium derivatives and their substance P (SP) antagonist activity are described. All compounds were evaluated for their ability to displace SP from neurokinin-1 (NK-1) receptor sites using standard receptor binding methodology (rat forebrain membrane). 1,3-Diethyl-2-[3-(1,3-dihydro-1,3,3-trimethyl-2H-indol-2-ylidene)-1-propenyl]-1H-naphth[2,3-d]imidazolium chloride (7a), a representative compound in this series, was further evaluated for SP antagonist activity in a guinea pig ileum contractility assay. In vivo SP antagonist activity of 7a was demonstrated using SP-induced salivation and paw edema models performed in rats.

  DOI：

  10.1021/jm00085a015

文献信息

• STETSENKO, A. V.;YARMOLYUK, S. N., YKP. XIM. ZH., 1981, 47, N 9, 964-966
  作者：STETSENKO, A. V.、YARMOLYUK, S. N.

  DOI：——

  日期：——
• Synthesis and substance P antagonist activity of naphthimidazolium derivatives
  作者：Kristine B. Lawrence、Bhaskar R. Venepalli、Kenneth C. Appell、Ramanuj Goswami、Margaret E. Logan、Bruce E. Tomczuk、John M. Yanni

  DOI：10.1021/jm00085a015

  日期：1992.4

  The synthesis of unsymmetrical naphth[2,3-d]imidazolium and bridged naphth[2,3-d]imidazolium derivatives and their substance P (SP) antagonist activity are described. All compounds were evaluated for their ability to displace SP from neurokinin-1 (NK-1) receptor sites using standard receptor binding methodology (rat forebrain membrane). 1,3-Diethyl-2-[3-(1,3-dihydro-1,3,3-trimethyl-2H-indol-2-ylidene)-1-propenyl]-1H-naphth[2,3-d]imidazolium chloride (7a), a representative compound in this series, was further evaluated for SP antagonist activity in a guinea pig ileum contractility assay. In vivo SP antagonist activity of 7a was demonstrated using SP-induced salivation and paw edema models performed in rats.